TRPS1 (Transcriptional Repressor GATA Binding 1)

Among EMPD cases, perivulvar (n=10) and periscrotal (n=5) cases were consistently positive, whereas perianal lesions (n=10) showed no/weak expression. In summary, TRPS1 demonstrates universal expression in mammary PD of all ER/HER2 subgroups and in Toker cells, and corroborates recent reports regarding the utility of TRPS1 in site-of-origin studies.

ER-positive ZR75.1 breast cancer cells transduced with retroviral vectors were treated with endocrine (tamoxifen, fulvestrant) or CDK4/6i monotherapies (abemaciclib, palbociclib, ribociclib) or a combination of fulvestrant and ribociclib. Twenty of these loci were also identified as candidates for resistance to other CDK4/6i and to fulvestrant and ribociclib combination therapy, including TRPS1 and TRIM24-genes that are involved in resistance to endocrine therapy but have not yet been associated with resistance to CDK4/6i. The identification of unique and shared resistance-associated loci highlights the complexity of resistance pathways.

In this review, we present the most comprehensive and up-to-date evaluation of the utility and limitations of TRPS1 immunohistochemistry in dermatopathology. Our aim is to deepen understanding of this emerging marker and provide practical guidance on its optimal integration with established immunohistochemical panels to enhance diagnostic accuracy in routine practice.

The advantages of TRPS1 in the differential diagnosis of metastatic lesions and its possible role in prognostic panels are highlighted. Methodological limitations of the using marker, standardization needs and future perspectives for clinical implementation are also discussed in article.

It may be used in diagnosis of EOC; however, it is not a reliable prognostic marker. Alongside breast carcinoma, EOC should be considered in differential diagnosis it TRPS1 -positive metastatic lesions of unknown primary.

This case highlights the diagnostic complexity of acral adnexal tumors with overlapping morphologic features. Molecular testing, such as next-generation sequencing, can be an essential adjunct in distinguishing between morphologically similar adnexal neoplasms, thereby guiding accurate diagnosis and management.

We propose that the initial IHC panel should include TRPS1, CK7 and CK20. In TRPS1-negative cases, additional immunostains should be performed: CDX2 and SATB2 for colonic; p63, GATA3 and uroplakin II/III for urothelial; and PSA and NKX3.1 for prostatic secondary EMPD.

In addition, TRPS1 exhibited higher AUC values than GATA3 and adipophilin in differentiating primary and recurrent SCs, although the difference was not significant. Collectively, our findings indicate that the TRPS1/GATA3/adipophilin-based model demonstrated excellent discriminatory efficacy for eyelid malignancies (Kappa = 0.784, micro-average F1 = 0.882, AUC-ROC = 0.964 [95%CI:0.934-0.994]), achieving clinical-grade performance.

Here, we describe a case of occipital primary cutaneous myoepithelial carcinoma occurring in a 56-year-old patient. RNA sequencing was performed on the tumor which identified a TRPS1::PLAG1 fusion event which is to our knowledge, the first time this has been reported in the literature for a primary cutaneous myoepithelial carcinoma.

TRPS1 and SOX10 are the most specific marker combination for confirmation of primary and metastatic triple negative breast cancer. Knowledge of variations in immunohistochemical staining patterns in Paget disease can prevent misdiagnosis.

The treatment was changed to entrectinib targeted therapy, the PET/CT re-examination showed partial remission...Targeted therapies including NTRK3 inhibitors, show promise emphasizing the importance of multidisciplinary management for this malignancy. Awareness of BSC's metastatic potential and tailored therapeutic strategies are crucial for optimizing outcomes.